ELEVAI Biosciences CEO to Showcase Company’s Obesity and Muscle Loss Prevention Technology at UCLA LA-BEST 2024 Conference
With the discussion centred around current gaps in obesity knowledge and technology, CEO Dr. Jordan Plews will present ELEVAI Biosciences’ engineered probiotic approach for muscle loss prevention in combination with one or more GLP-1 receptor agonists in obesity.
ELEVAI Labs (NASDAQ: ELAB), a pioneering force in medical aesthetics, announced that Chief Executive Officer Dr. Jordan R. Plews, PhD will be presenting at the Los Angeles Bioscience Ecosystem Summit Twenty 24 (LA-BEST) conference on Thursday, May 23, 2024.
LA-BEST is the premier showcase for bioscience innovation hosted by UCLA Technology Development Group (UCLA TDG). The event is a collaboration of ~1,000 participants across the Los Angeles area to promote biotech innovation and to foster partnerships between academic institutions, the investment community, and the biopharma industry. Leading bioscience translational research programs and startups will be showcased where Southern California Institutions have significant expertise, pioneering research, and resource commitments directed toward developing innovative patient therapies.
Conference Details:
- What: UCLA LA-BEST 2024 Conference
- Where: Luskin Conference Center on the UCLA Campus
- When: Thursday May 23, 2024
- Website: Click Here
Read Now: ELEVAI Labs: A Strategic Expansion in Biosciences and Skincare
ELEVAI Labs expands reach with new distribution partnerships, licensing agreement for therapeutic assets targeting obesity and the formation of skincare and biosciences subsidiaries.
Dr. Plews will speak as part of the session titled “Hot Topic: Metabolism”, where invited panelists will discuss the current gaps in obesity knowledge and technology and emerging solutions. Dr. Plews will be presenting ELEVAI Biosciences’ engineered probiotic approach for muscle loss prevention in combination with one or more GLP-1 receptor agonists in obesity.
Dr. Jordan R. Plews, PhD, CEO of ELEVAI Biosciences, commented on the discussion, stating:
“Myostatin is being tested in combination with GLP-1 drugs as it’s demonstrated to be a clinically validated target with potential in muscle mass and strength building. I’m excited to share with the scientific and investment community at LA-BEST why we believe that our lead clinical candidate EL-22 offers a differentiated, oral approach as compared to other myostatin strategies being tested in obesity. Our approach induces mucosal immunity through the body’s own anti-myostatin antibodies, which could have an important role in addressing the unmet medical need of obese patients, who need to preserve muscle while losing weight.”
Shares of ELEVAI Labs (NASDAQ: ELAB) last traded at $0.66, down -0.77% today.
Learn more about ELEVAI Labs: Website | Investor Deck | ELAB Chart
Follow ELEVAI on Social Media: Instagram | Facebook | LinkedIn | Twitter | YouTube
Join the Discussion in the Wealthy VC Investor Group
Have a Stock Tip or New Story Suggestion? Email us at Invest@WealthyVC.com
Elevai Labs Inc. is a paid client of Wealthy VC.
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.
